Deputy USPTO Director Teresa Stanek Rea has issued a retraction of her statement regarding Administration support for 12 years of exclusive rights in test data for biologic drugs, and moderated somewhat her statement on the India compulsory license for Nexavar. USTR also issued a statement on the issue of biologic test data in response to Rea’s earlier comments.
Hearings on intellectual property rights, 112th Congress
House of Representatives
April 26, 2012. Hearing on: “International Patent Issues: Promoting a Level Playing Field for American Industry Abroad” Subcommittee on Intellectual Property, Competition and the Internet. http://judiciary.edgeboss.net/wmedia/judiciary/ip/ip04262012.wvx
May 26, 2012. Hearing on: Implementation of the Leahy-Smith America Invents Act, Full Judiciary Committee Hearing. http://judiciary.edgeboss.net/wmedia/judiciary/full/fullcomm05162012.wvx
On June 27, 2012, Teresa Stanek Rea, the Deputy Under Secretary of Commerce for Intellectual Property and the Deputy Director of the United States Patent and Trademark Office (USPTO), testified at a hearing on: “International IP Enforcement: Protecting Patents, Trade Secrets and Market Access”, before the US House of Representatives, Judicary Committee, Subcommittee on Intellectual Property, Competition, and the Continue Reading →
The Global Fund just sent an email, which says that “your website which inaccurately reports that Mr Steiger will run VPP.” Here is the Global Fund email:
From: Andrew Hurst
Date: June 20, 2012 5:36:49 PM GMT+02:00
To: Thirukumaran Balasubramaniam
Subject: RE: Question on the Global Fund’s Voluntary Pooled Procurement?
Dear Thiru
Further to our conversation this week, here is our statement:
I recently sent the following letter to Andrew Bast, the editor of Foreign Affairs. The letter responds to a May 24, 2012 article by Devi Sridhar, Lawrence O. Continue Reading →
In preparation for the 65th World Health Assembly, held in Geneva from 21 May 2012 to 26 May 2012, the World Health Organization (WHO) prepared a document (A65/29 Add. 1, 5 April 2012) entitled “Voluntary contributions by fund and by donor for the financial period 2010-2011. Continue Reading →
This is a rough list of the recent ICE press releases mentioning counterfeit and pharmaceutical. It is quite clear that the overwhelming majority of counterfeit busts involve Viagra and other erectile dysfunction drugs, a problem that will probably resolve itself once the Pfizer patents on Viagra expire.
In my quick read of the ICE press releases, I found just 12 pharmaceutical counterfeiting cases in the ICE press releases from 2009 to May 2012, with 14 defendants.
